Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease

Trial Profile

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Coronary artery disease
  • Focus Biomarker; Pharmacodynamics
  • Acronyms RAND-CFR
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 26 Oct 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top